450 related articles for article (PubMed ID: 26795075)
21. FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma.
Gormley NJ; Ko CW; Deisseroth A; Nie L; Kaminskas E; Kormanik N; Goldberg KB; Farrell AT; Pazdur R
Clin Cancer Res; 2017 Nov; 23(22):6759-6763. PubMed ID: 28249893
[TBL] [Abstract][Full Text] [Related]
22. Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211.
Usmani SZ; Sexton R; Ailawadhi S; Shah JJ; Valent J; Rosenzweig M; Lipe B; Zonder JA; Fredette S; Durie B; Hoering A; Bartlett B; Orlowski RZ
Blood Cancer J; 2015 Aug; 5(8):e334. PubMed ID: 26252787
[No Abstract] [Full Text] [Related]
23. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.
Mateos MV; Hernández MT; Giraldo P; de la Rubia J; de Arriba F; Corral LL; Rosiñol L; Paiva B; Palomera L; Bargay J; Oriol A; Prosper F; López J; Arguiñano JM; Quintana N; García JL; Bladé J; Lahuerta JJ; Miguel JS
Lancet Oncol; 2016 Aug; 17(8):1127-1136. PubMed ID: 27402145
[TBL] [Abstract][Full Text] [Related]
24. Frequent occurrence of hypophosphatemia among multiple myeloma patients treated with elotuzumab: a single clinic retrospective study.
Regidor B; Swift R; Eades B; Emamy-Sadr M; Tarhini F; Spektor TM; Berenson JR
Ann Hematol; 2021 Apr; 100(4):1079-1085. PubMed ID: 33237342
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of elotuzumab for the treatment of multiple myeloma.
Gavriatopoulou M; Terpos E; Kastritis E; Dimopoulos MA
Expert Opin Drug Saf; 2017 Feb; 16(2):237-245. PubMed ID: 28060563
[TBL] [Abstract][Full Text] [Related]
26. Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study.
Mikhael J; Manola J; Dueck AC; Hayman S; Oettel K; Kanate AS; Lonial S; Rajkumar SV
Blood Cancer J; 2018 Aug; 8(9):86. PubMed ID: 30190454
[TBL] [Abstract][Full Text] [Related]
27. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth.
Dimopoulos MA; Lonial S; White D; Moreau P; Palumbo A; San-Miguel J; Shpilberg O; Anderson K; Grosicki S; Spicka I; Walter-Croneck A; Magen H; Mateos MV; Belch A; Reece D; Beksac M; Bleickardt E; Poulart V; Sheng J; Sy O; Katz J; Singhal A; Richardson P
Br J Haematol; 2017 Sep; 178(6):896-905. PubMed ID: 28677826
[TBL] [Abstract][Full Text] [Related]
28. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial.
Usmani SZ; Schjesvold F; Oriol A; Karlin L; Cavo M; Rifkin RM; Yimer HA; LeBlanc R; Takezako N; McCroskey RD; Lim ABM; Suzuki K; Kosugi H; Grigoriadis G; Avivi I; Facon T; Jagannath S; Lonial S; Ghori RU; Farooqui MZH; Marinello P; San-Miguel J;
Lancet Haematol; 2019 Sep; 6(9):e448-e458. PubMed ID: 31327689
[TBL] [Abstract][Full Text] [Related]
29. The role of elotuzumab in the treatment of relapsed or refractory multiple myeloma.
Comeau JM; Kelly K; Jean GW
Am J Health Syst Pharm; 2018 Jan; 75(2):55-66. PubMed ID: 29317395
[TBL] [Abstract][Full Text] [Related]
30. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function.
Dimopoulos M; Alegre A; Stadtmauer EA; Goldschmidt H; Zonder JA; de Castro CM; Masliak Z; Reece D; Olesnyckyj M; Yu Z; Weber DM
Cancer; 2010 Aug; 116(16):3807-14. PubMed ID: 20564094
[TBL] [Abstract][Full Text] [Related]
31. Lenalidomide is effective and safe for the treatment of patients with relapsed multiple myeloma and very severe renal impairment.
João C; Freitas J; Gomes F; Geraldes C; Coelho I; Neves M; Lúcio P; Esteves S; Esteves GV
Ann Hematol; 2016 May; 95(6):931-6. PubMed ID: 27068406
[TBL] [Abstract][Full Text] [Related]
32. Elotuzumab: First Global Approval.
Markham A
Drugs; 2016 Mar; 76(3):397-403. PubMed ID: 26809244
[TBL] [Abstract][Full Text] [Related]
33. Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.
Yee AJ; Bensinger WI; Supko JG; Voorhees PM; Berdeja JG; Richardson PG; Libby EN; Wallace EE; Birrer NE; Burke JN; Tamang DL; Yang M; Jones SS; Wheeler CA; Markelewicz RJ; Raje NS
Lancet Oncol; 2016 Nov; 17(11):1569-1578. PubMed ID: 27646843
[TBL] [Abstract][Full Text] [Related]
34. Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.
Salwender H; Bertsch U; Weisel K; Duerig J; Kunz C; Benner A; Blau IW; Raab MS; Hillengass J; Hose D; Huhn S; Hundemer M; Andrulis M; Jauch A; Seidel-Glaetzer A; Lindemann HW; Hensel M; Fronhoffs S; Martens U; Hansen T; Wattad M; Graeven U; Munder M; Fenk R; Haenel M; Scheid C; Goldschmidt H
BMC Cancer; 2019 May; 19(1):504. PubMed ID: 31138244
[TBL] [Abstract][Full Text] [Related]
35. Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma.
Shah J; Usmani S; Stadtmauer EA; Rifkin RM; Berenson JR; Berdeja JG; Lyons RM; Klippel Z; Chang YL; Niesvizky R
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):570-578.e1. PubMed ID: 31326409
[TBL] [Abstract][Full Text] [Related]
36. An open-label, pharmacokinetic study of lenalidomide and dexamethasone therapy in previously untreated multiple myeloma (MM) patients with various degrees of renal impairment - validation of official dosing guidelines.
Chen CI; Cao Y; Trudel S; Reece DE; Kukreti V; Tiedemann R; Prica A; Paul H; Le LW; Levina O; Kakar S; Lau A; Chen H; Chen E
Leuk Lymphoma; 2020 Aug; 61(8):1860-1868. PubMed ID: 32476520
[TBL] [Abstract][Full Text] [Related]
37. The Clinical Pharmacology of Elotuzumab.
Passey C; Sheng J; Mora J; Tendolkar A; Robbins M; Dodge R; Roy A; Bello A; Gupta M
Clin Pharmacokinet; 2018 Mar; 57(3):297-313. PubMed ID: 28779463
[TBL] [Abstract][Full Text] [Related]
38. Elotuzumab and dexamethasone for relapsed or refractory multiple myeloma patients: A retrospective study.
Gross Z; Rahbari A; Wirtschafter E; Spektor TM; Udd KA; Bujarski S; Ghermezi M; Nosrati JD; Vidisheva A; Eades B; Cecchi G; Maluso T; Swift R; Berenson JR
Eur J Haematol; 2018 Jun; 100(6):621-623. PubMed ID: 29524348
[TBL] [Abstract][Full Text] [Related]
39. Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 German centers.
Oehrlein K; Langer C; Sturm I; Pönisch W; Hahn-Ast C; Kuhn S; Weisel KC
Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):191-6. PubMed ID: 22341857
[TBL] [Abstract][Full Text] [Related]
40. Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers.
Hose D; Schreder M; Hefner J; Bittrich M; Danhof S; Strifler S; Krauth MT; Schoder R; Gisslinger B; Einsele H; Gisslinger H; Knop S
J Cancer Res Clin Oncol; 2021 Jan; 147(1):205-212. PubMed ID: 32683487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
